Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 2:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 340 matching trials from the live ClinicalTrials.gov search.
Conditions
Leukemia, Lymphoma
Interventions
SCRI-huCAR19v1, SCRI-huCAR19v2
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Year to 30 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2036
U.S. locations
2
States / cities
Los Angeles, California • Seattle, Washington
Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
CD19x22 CAR T
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
3 Months to 30 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Pediatric, Acute Myeloid Leukemia, Refractory
Interventions
CART123 cells; cyclophosphamide; fludarabine
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
1 Year to 29 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Neoplasms
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
9 Years to 16 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Stanford, California
Conditions
Leukemia
Interventions
cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, leucovorin calcium, mercaptopurine, methotrexate, pegaspargase, thioguanine, vincristine sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 9 Years
Enrollment
838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
108
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 82 more
Conditions
Kidney Cancer, Leukemia, Lymphoma, Myelodysplastic Syndromes, Neuroblastoma, Sarcoma
Interventions
filgrastim, allogeneic bone marrow transplantation
Biological · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
2
States / cities
Nashville, Tennessee • Seattle, Washington
Conditions
Pediatric Cancer, Leukemia, Sarcoma, Brain Tumors
Interventions
Not listed
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
57,816 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2030
U.S. locations
1
States / cities
Arcadia, California
Conditions
Acute Lymphoblastic Leukemia, Non Hodgkins Lymphoma
Interventions
Erwinase
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Memphis, Tennessee
Completed Not applicable Interventional Accepts healthy volunteers Results available

Inclusion Appeal Videos and Intent to Register for Pediatric Clinical Trials

NCT06138145
Conditions
Patient Participation, Pediatric ALL
Interventions
Video, Survey
Other · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Solid Tumor, Leukemia, Lymphoma, Brain Tumor
Interventions
IMPACT, ESO
Behavioral · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
0 Years to 18 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
3
States / cities
Cincinnati, Ohio • Dayton, Ohio • Oklahoma City, Oklahoma
Conditions
Leukemia
Interventions
Dexamethosone
Drug
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
5 Years to 21 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Memphis, Tennessee
Completed Not applicable Interventional Results available

Insomnia Prevention in Children With Acute Lymphoblastic Leukemia

NCT05866887
Conditions
Pediatric Acute Lymphoblastic Leukemia, Leukemia, Acute Lymphoblastic Leukemia
Interventions
Sleep ALL Night
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
4 Years to 12 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Acute Lymphoblastic Leukemia, Pediatric
Interventions
Use of Virtual Reality Headset
Other
Lead sponsor
Children's National Research Institute
Other
Eligibility
7 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Acute Lymphoblastic Leukemia
Interventions
6-Mercaptopurine
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
4 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Kansas City, Missouri
Conditions
Leukemia
Interventions
Dasatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
1 Day to 18 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 11 more
Conditions
AML, Childhood
Interventions
Nivolumab, 5-azacytidine
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 30 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
12
States / cities
Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 9 more
Conditions
Pediatric ALL
Interventions
Standard of care drug
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2033
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Lymphoma, Peripheral T-cell Lymphoma
Interventions
Temsirolimus, Etoposide, Cyclophosphamide, Methotrexate, Hydrocortisone, Cytarabine
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
25
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 22 more
Conditions
Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia
Interventions
Fludarabine, Cyclophosphamide, Mesna, CD19-CD22 CAR T cell infusion
Drug · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Chronic Graft-versus-Host-Disease, Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation, Blood Cancer, Non-Malignant Hematologic and Lymphocytic Disorder
Interventions
Not listed
Lead sponsor
University of British Columbia
Other
Eligibility
0 Years to 24 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
11
States / cities
San Francisco, California • Denver, Colorado • Atlanta, Georgia + 8 more
Active, not recruiting Phase 1 Interventional

CD22 Redirected Autologous T Cells for ALL

NCT02650414
Conditions
B Cell Leukemias, B Cell Lymphomas
Interventions
Cohort 1, Cohorts 2, Cohort 3, Cohort 3A
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
1 Year to 29 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2037
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Acute Myeloid Leukemia
Interventions
ASTX727, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Conditions
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory, Pediatric ALL
Interventions
CD19-CAR(Mem) T-cells, Cyclophosphamide, Fludarabine, Mesna, CliniMACS, Leukapheresis
Biological · Drug · Device + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Interventions
midostaurin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
3 Months to 18 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Seattle, Washington